NuCana PLC (NCNA)
| Market Cap | 131.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -54.49M |
| Shares Out | 52.16M |
| EPS (ttm) | -1.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 451,833 |
| Open | 2.56 |
| Previous Close | 2.57 |
| Day's Range | 2.50 - 2.59 |
| 52-Week Range | 1.88 - 7.83 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+577.3%) |
| Est. Earnings Date | Nov 18, 2021 |
About NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian can...
Analyst Forecast
According to 8 analysts, the average rating for NuCana stock is "Strong Buy." The 12-month stock price forecast is 17.00, which is an increase of 577.29% from the latest price.
News
NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing
NuCana (NCNA) stock is surging higher on Wednesday after the company revealed fast track designation from the FDA for Acelarin. The post NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing ...
Why Are NuCana Shares Moving Higher On Wednesday?
The FDA has granted Fast Track designation to NuCana plc's (NASDAQ: NCNA) Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. The Company recently announced ...
NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Tr...
EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-103...
NuCana Announces Four Poster Presentations at the ESMO Congress 2021
NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer
NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary...
Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022
7 Bargain Stocks to Buy Under $5 With the Right Catalysts
The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalyst...
NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update
EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical...
7 Penny Stocks to Buy if You Want Potential Multibaggers
Here's a list of interesting penny stocks to buy that have lucrative prospects if you're willing to risk it for tremendous upside. The post 7 Penny Stocks to Buy if You Want Potential Multibaggers appea...
NuCana Reports First Quarter 2021 Financial Results and Provides Business Update
Presented Encouraging Clinical Data at ASCO-GI and AACR
NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit
EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one...
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2...
NuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
Presented Encouraging Clinical Data for NUC-3373 and NUC-7738
3 Biotech Stocks That Jumped Last Week
Find out what led to the biotech industry's biggest gains.
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal C...
Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy
NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session
NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
NuCana Appoints Andrew Kay as Board Chairman
Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors
Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Publishe...
Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed
NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update
Completed Successful $ 8 0 million Public Offering
NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present a...
NuCana to Present at the Jefferies Virtual London Healthcare Conference
EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present a...
Why NuCana (NCNA) Might Surprise This Earnings Season
NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar
Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering
NuCana (NCNA) Surges: Stock Moves 6.3% Higher
NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
NuCana Presents Three Posters at the ESMO Virtual Congress 2020
Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)
NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option t...
EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, ann...